Retrieve available abstracts of 15 articles: HTML format
Single Articles
June 2025
JIANG F, Guan CL, Jiao LZ, Xu T, et al Efficacy and Safety of Biweekly Single-Dose Actinomycin D vs Multiday
Methotrexate in Low-Risk Gestational Trophoblastic Neoplasia: A Prospective
Multicenter Randomized Trial.
Ann Oncol. 2025 Jun 19:S0923-7534(25)00811-7. doi: 10.1016/j.annonc.2025. PubMedAbstract available
MAYADEV J, Vazquez Limon JC, Ramirez Godinez FJ, Leiva M, et al Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse
and survival in patients with locally advanced cervical cancer: phase III CALLA
trial analyses.
Ann Oncol. 2025 Jun 2:S0923-7534(25)00738-0. doi: 10.1016/j.annonc.2025. PubMedAbstract available
May 2025
HARDY-BESSARD AC, Pujade-Lauraine E, Moore RG, Montestruc F, et al Dostarlimab and niraparib in primary advanced ovarian cancer.
Ann Oncol. 2025 May 30:S0923-7534(25)00201-7. doi: 10.1016/j.annonc.2025. PubMedAbstract available
HUIS IN 'T VELD EA, Van Assche IA, Van Calsteren K, Salaets T, et al LONG-TERM DEVELOPMENT OF 12- AND 15-YEAR-OLD OFFSPRING AFTER MATERNAL CANCER
DIAGNOSIS DURING PREGNANCY: A PROSPECTIVE MULTICENTRE COHORT STUDY.
Ann Oncol. 2025 May 6:S0923-7534(25)00171-1. doi: 10.1016/j.annonc.2025. PubMedAbstract available
March 2025
CHAMBERS LM, Eskander RN, O'Malley DM Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive
ovarian cancer in the post-PARP era.
Ann Oncol. 2025;36:244-246. PubMed
November 2024
SECORD AA, Lewin SN, Murphy CG, Cecere SC, et al The Efficacy and Safety of Mirvetuximab Soravtansine in FRalpha-Positive, Third-Line
and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2
PICCOLO Trial.
Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024. PubMedAbstract available
HARTER P, Marth C, Mouret-Reynier MA, Cropet C, et al Efficacy of subsequent therapies in patients with advanced ovarian cancer who
relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25
trial.
Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024. PubMedAbstract available
LORUSSO D, Fuca G KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy
for dMMR endometrial cancer?
Ann Oncol. 2024;35:925-927. PubMed
October 2024
LORUSSO D, Colombo N, Dubot C, Caceres MV, et al Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final
Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study.
Ann Oncol. 2024 Oct 9:S0923-7534(24)04033-X. doi: 10.1016/j.annonc.2024. PubMedAbstract available
September 2024
MONK BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, et al Niraparib first-line maintenance therapy in patients with newly diagnosed
advanced ovarian cancer: final overall survival results from the
PRIMA/ENGOT-OV26/GOG-3012 trial.
Ann Oncol. 2024 Sep 14:S0923-7534(24)03762-1. doi: 10.1016/j.annonc.2024.08.2241 PubMedAbstract available
August 2024
VAN GORP T, Cibula D, Lv W, Backes F, et al ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy
in Patients With Newly Diagnosed, High-Risk Endometrial Cancer.
Ann Oncol. 2024 Aug 23:S0923-7534(24)03822-5. doi: 10.1016/j.annonc.2024.08.2242 PubMedAbstract available
COLOMBO N, Caruso G, Jalving M Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story.
Ann Oncol. 2024;35:686-688. PubMed
June 2024
POWELL MA, Bjorge L, Willmott L, Novak Z, et al Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab
plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial.
Ann Oncol. 2024 Jun 10:S0923-7534(24)00721-X. doi: 10.1016/j.annonc.2024. PubMedAbstract available
May 2024
PIGNATA S, Califano D, Lorusso D, Arenare L, et al MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling
in first-line endometrial cancer therapy.
Ann Oncol. 2024 May 2:S0923-7534(24)00128-5. doi: 10.1016/j.annonc.2024. PubMedAbstract available
February 2024
BOGANI G, Monk BJ, Powell MA, Westin SN, et al Adding immunotherapy to first-line treatment of advanced and metastatic
endometrial cancer.
Ann Oncol. 2024 Feb 29:S0923-7534(24)00056-5. doi: 10.1016/j.annonc.2024. PubMedAbstract available